BOSTON, June 05, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapeutics for the treatment of chronic pain, today ...

17, 2019 (GLOBE NEWSWIRE) -- Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-addictive therapies for the treatment of chronic pain, today announced completion ...

Centrexion Therapeutics, which is developing non-opioid therapies for chronic pain, revived its IPO with financial results for the six months ended June 30, 2019, in an amendment filed with the ...

Centrexion Therapeutics, which is developing non-opioid therapies for chronic pain, postponed its IPO on Thursday. It had filed to raise $75 million by offering 5 million shares at a price range ...

BOSTON--(BUSINESS WIRE)--Centrexion Therapeutics Corporation, a company focused on developing non-opioid, non-steroidal therapeutics for the treatment of chronic pain, today announced that Nick ...

Startup Centrexion Therapeutics Corp. has struck a nearly $1 billion drug-licensing deal with Eli Lilly & Co. for a non-opioid pain medication that could be an addiction-free alternative.

Centrexion Therapeutics Corp., a pain treatment developer founded by the former leaders of Pfizer Inc. and Celgene Corp., on Friday disclosed plans to go public. The Boston-based company said the ...